floxacillin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, 6-aminopenicillanic acid derivatives 1183 5250-39-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • floxacillin
  • fluocloxacilin
  • flucloxacillin
  • fluoxacillin
  • flucloxacillin sodium
Antibiotic analog of CLOXACILLIN.
  • Molecular weight: 453.87
  • Formula: C19H17ClFN3O5S
  • CLOGP: 2.66
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 112.74
  • ALOGS: -3.92
  • ROTB: 3

Drug dosage:

DoseUnitRoute
2 g O
2 g P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 146.96 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.19 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1962 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metabolic acidosis 267.41 51.25 51 258 5947 2351829
Clostridium difficile infection 136.65 51.25 26 283 2864 2354912
Drug interaction 123.08 51.25 37 272 29126 2328650
Liver function test abnormal 101.36 51.25 24 285 7466 2350310
Maternal exposure during pregnancy 71.53 51.25 21 288 14842 2342934
Diarrhoea 65.65 51.25 31 278 83533 2274243
Renal failure 59.88 51.25 19 290 17330 2340446
Eczema herpeticum 58.89 51.25 7 302 25 2357751

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metabolic acidosis 184.73 72.61 38 189 5364 1741190
Pyroglutamate increased 99.15 72.61 11 216 12 1746542
Clostridium difficile infection 93.15 72.61 18 209 1763 1744791
Cellulitis 74.99 72.61 19 208 6449 1740105

Pharmacologic Action:

SourceCodeDescription
ATC J01CF05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Beta-lactamase resistant penicillins
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drug

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.76 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Androgen receptor Nuclear hormone receptor IC50 6.25 WOMBAT-PK
Matrix metalloproteinase-9 Enzyme IC50 4.19 WOMBAT-PK
Penicillin-binding protein 1A Enzyme WOMBAT-PK

External reference:

IDSource
D005436 MESH_DESCRIPTOR_UI
N0000167002 NUI
C0016267 UMLSCUI
D01249 KEGG_DRUG
43B2M34G2V UNII
2308 INN_ID
96067005 SNOMEDCT_US
387544009 SNOMEDCT_US
4448 RXNORM
003516 NDDF
CHEMBL222645 ChEMBL_ID
DB00301 DRUGBANK_ID
CHEBI:5098 CHEBI
21319 PUBCHEM_CID

Pharmaceutical products:

None